Johnson & Johnson secures option to acquire in-vivo CAR-T developer Sail Biomedicines for up to $2.6 billion
Johnson & Johnson announced a strategic partnership with Sail Biomedicines, a Flagship Pioneering‑backed startup, that includes an upfront cash payment and an equity investment.
The initial payment totals $785 million, including a $465 million equity stake, intended to move Sail’s lead preclinical program, SAIL-0839, which aims to reprogram immune cells inside the body.
The deal also grants J&J an exclusive option to buy Sail for $2.58 billion in the future, aligning the company with other large pharma firms that have recently invested in in‑vivo cell‑therapy platforms.
Sail has not disclosed the specific disease targets for its technology, but the agreement highlights growing interest in applying in‑vivo CAR‑T approaches beyond cancer, potentially to autoimmune conditions.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that